
The FDA has approved neladalkib for TKI-pretreated advanced ALK-positive NSCLC based on ALKOVE-1, requiring only 1 prior line of treatment in those who received prior alectinib.
Dr. Bose shares his vision for the future management of patients with intermediate myelofibrosis, including the unmet needs with current treatment options and the emerging data he is closely following.
Case: Intermediate-Risk Primary Myelofibrosis in a 68-Year-Old Woman
Clinical Presentation:
PM: No known comorbidities
Initial Clinical Workup and Diagnosis:
Initial Treatments:






